About VWDHigh-Quality VWFFlexibility and DosingCSL Behring CommitmentResources and ToolsHelp Your Patients Learn to Self-infuse Humate-P®Pharmacy ProgramRequest More InformationEducational Program LinksAllAboutBleeding.comDosage CalculatorCustomizable Patient MaterialsVWF Densitometric AnalysisNews and EventsImportant Safety Information for Humate-P®Prescribing Information for Humate-P®Dosage CalculatorVWF Densitometric AnalysisRequest More InfoHumate-P® for Patients

Customizable Patient Materials

Here you will find some of our most requested patient materials. You can customize these materials with your own office contact information and provide copies for your patients. Just follow these three steps:

  1. Click below to open the PDF file you would like to customize.
  2. Enter your office information in the spaces provided.
  3. Save the customized PDF to your desktop or print the PDF using the menu bar at the top of the form.

Medications to Avoid
This link provides a listing of medication your VWD patients should avoid.

Activities to Enjoy
This link provides information on physical activities.

My Journal
Your female patients with VWD can use this journal to keep track of their menstrual cycles and related information. It can also be a helpful tool for their next visit with you.

Get Adobe Reader


Important Safety Information


Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

© CSL Behring 2010. The product information presented on this site is intended for US residents only.